Crystalys Lands $205M to Advance Gout Drug Dotinurad
Crystalys Therapeutics has launched with $205 million in funding to advance the gout drug dotinurad, a treatment already approved in multiple Asian countries.
Dotinurad has shown superior uric acid reduction compared to other treatments like Uloric.
The company plans to conduct global Phase 3 studies to expand the drug's reach to the U.S. and Europe.